Details for TA155
TA155 Ranibizumab and Pegaptanib -Macular degeneration (age-related)

Comparator
Number of people eligible for treatment per 100,000 population
6667
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
+£4,985.86
Annual budgetary impact
tbc
Additional information for costs
Details for TA129
TA129 Bortezomib monotherapy - relapsed multiple myeloma

Comparator
Number of people eligible for treatment per 100,000 population
5.5
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£52,616.27
New treatment cost per eligible individual
+£9,514.50
Annual budgetary impact
tbc
Additional information for costs
Details for TA111
TA111 Donepezil, galantamine, rivastigmine (review) and memantine- Alzheimer's disease

Comparator These drugs were previously recommended for both mild and moderate Alzheimer's disease
Number of people eligible for treatment per 100,000 population
447.3
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
£-25,753.20
New treatment cost per eligible individual
£.00
Annual budgetary impact
tbc
Additional information for costs
Details for TA195
TA195 Biologics - rheumatoid arthritis

Comparator
Number of people eligible for treatment per 100,000 population
15.0254175765
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£43,844.02
New treatment cost per eligible individual
+£9,601.32
Annual budgetary impact
tbc
Additional information for costs
includes only drug costs
Details for TA192
TA192 Gefitinib- Lung cancer (non-small-cell, first line)

Comparator
Number of people eligible for treatment per 100,000 population
1.2944952
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£3,411.65
New treatment cost per eligible individual
+£9,760.00
Annual budgetary impact
tbc
Additional information for costs
DA=£1847.22
Details for TA190
TA190 Premetrexed- Lung cancer

Comparator premetrexed compared with best suportive care
Number of people eligible for treatment per 100,000 population
12.317684652
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£5,678.95
New treatment cost per eligible individual
+£11,526.00
Annual budgetary impact
tbc
Additional information for costs
Drug administration £911.89 Adverse Events £28.42
Details for TA188
TA188 Somatropin - growth failure children

Comparator somatropin
Number of people eligible for treatment per 100,000 population
8
eligible
[image to go here]
Clinical Impact
adhere and continue 76.5%
Change in treatment cost per 100,000 population
+£38,670.32
New treatment cost per eligible individual
+£7,163.70
Annual budgetary impact
adhere and continue 76.5%
Additional information for costs
Testing administration =£5847.5 Testing/adminitration £9354.6 * does not account for non responders
Details for TA187
TA187 Infliximab (review) and adalimumab -Crohn’s disease

Comparator Infliximab was recommended as an episodic treatment rather than maintenance, so this replaces that indication in three different population groups
Number of people eligible for treatment per 100,000 population
25.5976437802
eligible
[image to go here]
Clinical Impact
59% expected to respond to infliximab; 54% to adalimumab
Change in treatment cost per 100,000 population
+£107,027.20
New treatment cost per eligible individual
+£15,383.45
Annual budgetary impact
59% expected to respond to infliximab; 54% to adalimumab
Additional information for costs
Details for TA183
TA183 Topotecan -cervical cancer

Comparator
Number of people eligible for treatment per 100,000 population
0.0992539125
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£378.06
New treatment cost per eligible individual
+£3,809.00
Annual budgetary impact
tbc
Additional information for costs
Administration £443.72
Details for TA182
TA182 Prasugrel -acute coronary syndrome

Comparator clopidrogel
Number of people eligible for treatment per 100,000 population
72.316416
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£8,624.22
New treatment cost per eligible individual
+£628.48
Annual budgetary impact
tbc
Additional information for costs
reduction in rate of hospitalistations SAVING £2337
Details for TA181
TA181 Pemetrexed -Lung Cancer

Comparator pemetrexed/cisplatin compared with gemcitabine/cisplatin
Number of people eligible for treatment per 100,000 population
7
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£6,631.76
New treatment cost per eligible individual
+£4,736.34
Annual budgetary impact
tbc
Additional information for costs
AE £1680 DA £3842.61: New AE £550.11 DA £921
Details for TA179
TA179 Sunitinib -GI tumours

Comparator sunitinib compared with best supportive care
Number of people eligible for treatment per 100,000 population
0.405
eligible
[image to go here]
Clinical Impact
20% of patients do not respond or stop taking during first cycle
Change in treatment cost per 100,000 population
+£3,604.18
New treatment cost per eligible individual
+£8,899.20
Annual budgetary impact
20% of patients do not respond or stop taking during first cycle
Additional information for costs
New AE £4.46 new support £67.89
Details for TA177
TA177 Alitretinoin -Eczema

Comparator alitretinoin compared with ciclosporin
Number of people eligible for treatment per 100,000 population
60
eligible
[image to go here]
Clinical Impact
52.3% do not respond
Change in treatment cost per 100,000 population
£-103,277.63
New treatment cost per eligible individual
+£2,404.66
Annual budgetary impact
52.3% do not respond
Additional information for costs
Old support = £10906 New support = £15039 Old AE= £526 New AE = £452
Details for TA176
TA176 Colorectal cancer - Cetuximab

Comparator cetuximab in combination with FOLFOX compared with FOLFOX alone
Number of people eligible for treatment per 100,000 population
3
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£23,730.63
New treatment cost per eligible individual
+£8,256.00
Annual budgetary impact
tbc
Additional information for costs
Details for TA174
TA174 Rituximab -Leukaemia

Comparator Rituximab with fludarabine and cyclophosphamide compared with fludarabine and cyclophosphamide
Number of people eligible for treatment per 100,000 population
3
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£8,099.06
New treatment cost per eligible individual
+£8,167.72
Annual budgetary impact
tbc
Additional information for costs
Details for TA169
TA169 Sunitinib - renal cell carcinoma

Comparator best supportive care (sunitinib is indicated for people whom immunotherapy not suitable)
Number of people eligible for treatment per 100,000 population
4
eligible
[image to go here]
Clinical Impact
proportion of patients who do not respond or drop out after first cycle 37.5%
Change in treatment cost per 100,000 population
+£7,541,392.57
New treatment cost per eligible individual
+£1,961,875.00
Annual budgetary impact
proportion of patients who do not respond or drop out after first cycle 37.5%
Additional information for costs
Patient consultations £670.52 Adverse events £352
Details for TA162
TA162 Erlotinib -non-small cell lung cancer

Comparator recommended as an alternative to docetaxel
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact
Additional information for costs
Considered by NICE not to have a great impact
Details for TA172
TA172 Cetuximab -squamous cell carcinoma

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Treatment NOT recommended
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Treatment NOT recommended
Additional information for costs
Treatment NOT recommended
Details for TA168
TA168 Amantadine, oseltamivir and zanamivir -Influenza (review of existing guidance No. 58)

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact
Additional information for costs
Considered by NICE not to have a great impact
Details for TA167
TA167 Endovascular stent-grafts -Abdominal aneurysm

Comparator Conventional (open) surgical repair (OSR) compared with Endovascular aneurysm repair (EVAR)
Number of people eligible for treatment per 100,000 population
2.5
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£13,079.71
New treatment cost per eligible individual
+£15,416.00
Annual budgetary impact
tbc
Additional information for costs
Details for TA165
TA165 Organ preservation (renal)- machine perfusion and static storage

Comparator DEVICE : LifePort Kidney transporter and Belzer University of Wisconson (BelzerUW) storage solution or Marshalls hypertonic citrate solution.
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Additional information for costs
Details for TA164
TA164 Febuxostat -Hyperuricaemia

Comparator Febuxostat compared with fixed-dose allopurinol
Number of people eligible for treatment per 100,000 population
46
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£13,732.84
New treatment cost per eligible individual
+£302.92
Annual budgetary impact
tbc
Additional information for costs
Details for TA163
TA163 Infliximab -Ulcerative colitis

Comparator Infliximab compared with standard care
Number of people eligible for treatment per 100,000 population
60
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£302,100.00
New treatment cost per eligible individual
+£5,035.00
Annual budgetary impact
tbc
Additional information for costs
DA=£10800
Details for TA160
TA160 Primary prevention - Osteoporosis

Comparator Alendronate, etidronate, risedronate, raloxifene and strontium ranelate
Number of people eligible for treatment per 100,000 population
1003
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
£-5,438.90
New treatment cost per eligible individual
+£67.17
Annual budgetary impact
tbc
Additional information for costs
Details for TA159
TA159 Spinal cord stimulation - Pain (chronic neuropathic or ischaemic)

Comparator None
Number of people eligible for treatment per 100,000 population
2
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£14,472.18
New treatment cost per eligible individual
+£20,096.00
Annual budgetary impact
tbc
Additional information for costs
Details for TA161
TA161 Alendronate, etidronate, risedronate, raloxifene and strontium ranelate - osteoporotic fragility fractures in postmenopausal women

Comparator Raloxifene no longer recommended - so effect of guidance is to increase proportion receiving bisphosphonates.
Number of people eligible for treatment per 100,000 population
4214
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£35,761.29
New treatment cost per eligible individual
+£84.19
Annual budgetary impact
tbc
Additional information for costs
Details for TA158
TA158 Amantadine, oseltamivir and zanamivir for post exposure Influenza (prophylaxis)

Comparator recommendation is to extend treatment to this age-group who are currently not treated with this
Number of people eligible for treatment per 100,000 population
1467
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£4,594.43
New treatment cost per eligible individual
+£14.98
Annual budgetary impact
tbc
Additional information for costs
Details for TA157
TA157 Venous thromboembolism-dabigatran

Comparator Low-Molecular-weight heparin, fondaparinux
Number of people eligible for treatment per 100,000 population
181
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£512.59
New treatment cost per eligible individual
+£76.37
Annual budgetary impact
tbc
Additional information for costs
Drug administration £685.1 (13% of THR receive approximately 20 home visits by a community nurse at a cost per patient of £62) Dabigatran etexilate is orally administered so will not have these costs
Details for TA153
TA153 Entecavir: Hepatitis B

Comparator Lamivudine, adefovir dipivoxil
Number of people eligible for treatment per 100,000 population
6
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£1,461.46
New treatment cost per eligible individual
+£4,600.00
Annual budgetary impact
tbc
Additional information for costs
Details for TA152
TA152 Drug-eluting stents -coronary artery disease

Comparator As a PCI for CAD only if: the target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15 mm, and the price difference between drug-eluting stents and bare-metal stents is no more than £300.
Number of people eligible for treatment per 100,000 population
105
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
£-10,294.19
New treatment cost per eligible individual
+£431.00
Annual budgetary impact
tbc
Additional information for costs
Details for TA146
TA146 Adalimumab -psoriasis

Comparator Ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation)
Number of people eligible for treatment per 100,000 population
14
eligible
[image to go here]
Clinical Impact
An estimated 43% will take adalimumab. This changes the ratios currently taking other biologics.
Change in treatment cost per 100,000 population
+£30,275.46
New treatment cost per eligible individual
+£7,167.83
Annual budgetary impact
An estimated 43% will take adalimumab. This changes the ratios currently taking other biologics.
Additional information for costs
Details for TA143
TA143 Adalimumab, etanercept and infliximab - ankylosing spondylitis

Comparator NSAIDS
Number of people eligible for treatment per 100,000 population
4.015
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£22,048.14
New treatment cost per eligible individual
+£5,720.25
Annual budgetary impact
tbc
Additional information for costs
Details for TA139
TA139 Continuous positive airway pressure - obstructive sleep apnoea/hypopnoea syndrome

Comparator
Number of people eligible for treatment per 100,000 population
1948.6
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£102,879.39
New treatment cost per eligible individual
+£875.57
Annual budgetary impact
tbc
Additional information for costs
Details for TA137
TA137 Rituximab - follicular non-Hodgkin's lymphoma

Comparator Currently patients can have chemotherapy without rituximab (27% of patients); after implementation of this guidance, this figure should go down to 0%
Number of people eligible for treatment per 100,000 population
2.7
eligible
[image to go here]
Clinical Impact
tbc
Change in treatment cost per 100,000 population
+£16,468.29
New treatment cost per eligible individual
+£7,275.96
Annual budgetary impact
tbc
Additional information for costs
Details for TA123
TA123 Varenicline -smoking cessation

Comparator
Number of people eligible for treatment per 100,000 population
936
eligible
[image to go here]
Clinical Impact
Change in treatment cost per 100,000 population
+£14,484.79
New treatment cost per eligible individual
+£131.69
Annual budgetary impact
Additional information for costs
Details for TA122
TA122 Alteplase -acute ischaemic stroke

Comparator
Number of people eligible for treatment per 100,000 population
120.2852
eligible
[image to go here]
Clinical Impact
Change in treatment cost per 100,000 population
+£11,108.58
New treatment cost per eligible individual
+£96.00
Annual budgetary impact
Additional information for costs
Details for TA119
TA119 Fludarabine monotherapy-chronic lymphocytic leukaemia

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact; no costing template
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact; no costing template
Additional information for costs
Considered by NICE not to have a great impact; no costing template
Details for TA124
TA124 Pemetrexed for the treatment of non-small-cell lung cancer

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact; no costing template
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact; no costing template
Additional information for costs
Considered by NICE not to have a great impact; no costing template
Details for TA132
TA132 Ezetimibe-(heterozygous-familial and non-familial) hypercholesterolaemia

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact; no costing template
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact; no costing template
Additional information for costs
Considered by NICE not to have a great impact; no costing template
Details for TA135
TA135 Mesothelioma - pemetrexed disodium

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact; no costing template
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact; no costing template
Additional information for costs
Considered by NICE not to have a great impact; no costing template
Details for TA141
TA141 Abatacept - rheumatoid arthritis

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Treatment NOT recommended
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Treatment NOT recommended
Additional information for costs
Treatment NOT recommended
Details for TA156
TA156 Routine antenatal anti-D prophylaxis -rhesus D negative women

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Considered by NICE not to have a great impact; no costing template
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Considered by NICE not to have a great impact; no costing template
Additional information for costs
Considered by NICE not to have a great impact; no costing template
Details for TA154
TA154 Telbivudine -chronic hepatitis B

Comparator
Number of people eligible for treatment per 100,000 population
0
eligible
[image to go here]
Clinical Impact
Treatment NOT recommended
Change in treatment cost per 100,000 population
£.00
New treatment cost per eligible individual
£.00
Annual budgetary impact
Treatment NOT recommended
Additional information for costs
Treatment NOT recommended